Stockreport

Capricor nabs accelerated review status in U.S. for Duchenne candidate CAP-1002; shares up 9% premarket [Seeking Alpha]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF Capricor nabs accelerated review status in U.S. for Duchenne candidate CAP-1002; shares up 9% premarketCapricor Therapeutics (NASDAQ:CAPR) is up9% premarket on modestly [Read more]